EyePoint Pharmaceuticals ... (EYPT)
undefined
undefined%
At close: undefined
7.96
6.49%
After-hours Dec 13, 2024, 05:55 PM EST

Company Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.

The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.

It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC.

It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery.

The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.

EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc. logo
Country United States
IPO Date Jan 27, 2005
Industry Biotechnology
Sector Healthcare
Employees 121
CEO Dr. Jay S. Duker M.D.

Contact Details

Address:
480 Pleasant Street
Watertown, Massachusetts
United States
Website https://eyepointpharma.com

Stock Details

Ticker Symbol EYPT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001314102
CUSIP Number 30233G209
ISIN Number US30233G2093
Employer ID 26-2774444
SIC Code 3826

Key Executives

Name Position
Dr. Jay S. Duker M.D. President, Chief Executive Officer & Director
George O. Elston CPA Executive Vice President & Chief Financial Officer

Latest SEC Filings

Date Type Title
Dec 04, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 07, 2024 10-Q Quarterly Report
Nov 07, 2024 8-K Current Report
Nov 06, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 04, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...